ROCK1 as a potential therapeutic target in osteosarcoma

Journal of Orthopaedic Research

Volumn 29, Issue 8, 2011, Pages 1259-1266

  Liu, Xianzhe ^a,b   Choy, Edwin ^a   Hornicek, Francis J ^a   Yang, Shuhua ^b   Yang, Cao ^b   Harmon, David ^a   Mankin, Henry ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

kinase; osteosarcoma; ROCK1

Indexed keywords

PROTEIN KINASE; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CELL VIABILITY; CHILD; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OSTEOSARCOMA CELL; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOBLASTS; OSTEOSARCOMA; PROGNOSIS; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79958792620     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21403     Document Type: Article

References (23)

1. Hayden JB, Hoang BH,. 2006. Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 37: 1-7. (Pubitemid 41719081)
2. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, et al. 2009. Osteosarcoma. J Am Acad Orthop Surg 17: 515-527.
3. Tan ML, Choong PF, Dass CR,. 2009. Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol Ther 8: 106-117.
4. Bacci G, Ferrari S, Mercuri M, et al. 1998. Neoadjuvant chemotherapy for extremity osteosarcoma-preliminary results of the Rizzoli's 4th study. Acta Oncol 37: 41-48. (Pubitemid 28179799)
5. Bielack SS, Kempf-Bielack B, Delling G, et al. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790. (Pubitemid 34111386)
6. Chou AJ, Geller DS, Gorlick R,. 2008. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327.
7. Link MP, Goorin AM, Miser AW, et al. 1986. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606. (Pubitemid 16118216)
8. Schwartz CL, Gorlick R, Teot L, et al. 2007. Multiple drug resistance in osteogenic sarcoma: Int0133 from the children's oncology group. J Clin Oncol 25: 2057-2062. (Pubitemid 46972791)
9. Kempf-Bielack B, Bielack SS, Jurgens H, et al. 2005. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (coss). J Clin Oncol 23: 559-568. (Pubitemid 46224233)
10. Duan Z, Ji D, Weinstein EJ, et al. 2010. Lentiviral shRNA screen of human kinases identifies plk1 as a potential therapeutic target for osteosarcoma. Cancer Lett 293: 220-229.
11. Yang C, Ji D, Weinstein EJ, et al. 2010. The kinase mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 31: 552-558.
12. Blume-Jensen P, Hunter T,. 2001. Oncogenic kinase signalling. Nature 411: 355-365. (Pubitemid 32467045)
13. Mercer SE, Ewton DZ, Shah S, et al. 2006. Mirk/dyrk1b mediates cell survival in rhabdomyosarcomas. Cancer Res 66: 5143-5150. (Pubitemid 43844936)
14. Duan Z, Choy E, Harmon D, et al. 2009. Insulin-like growth factor-i receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 8: 2122-2130.
15. Thomas V, Fikrig E,. 2007. Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of rock1 during infection. Cell Microbiol 9: 1730-1737. (Pubitemid 46958799)
16. Villalonga P, Fernandez de Mattos S, Ridley AJ,. 2009. Rhoe inhibits 4e-bp1 phosphorylation and eif4e function impairing cap-dependent translation. J Biol Chem 284: 35287-35296.
17. Deng L, Li G, Li R, et al. 2010. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 9: 875-884.
18. Pinner S, Sahai E,. 2008. Pdk1 regulates cancer cell motility by antagonising inhibition of rock1 by rhoe. Nat Cell Biol 10: 127-137. (Pubitemid 351194042)
19. Lin SL, Chiang A, Chang D, et al. 2008. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424. (Pubitemid 351397806)
20. Fritz G, Just I, Kaina B,. 1999. Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687. (Pubitemid 29214373)
21. Sahai E, Marshall CJ,. 2002. Rho-GTPases and cancer. Nat Rev Cancer 2: 133-142.
22. Kamai T, Tsujii T, Arai K, et al. 2003. Significant association of rho/rock pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632-2641. (Pubitemid 36842107)
23. Lane J, Martin TA, Watkins G, et al. 2008. The expression and prognostic value of rock i and rock ii and their role in human breast cancer. Int J Oncol 33: 585-593.